Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

1.

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, Crowley J, Barlogie B.

Blood. 2011 Sep 29;118(13):3512-24. doi: 10.1182/blood-2010-12-328252. Epub 2011 May 31.

PMID:
21628408
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Current status of bortezomib in the treatment of multiple myeloma.

Cavo M.

Curr Hematol Malig Rep. 2007 May;2(2):128-37. doi: 10.1007/s11899-007-0018-y. Review.

PMID:
20425361
[PubMed - indexed for MEDLINE]
3.

Bortezomib in the front-line treatment of multiple myeloma.

Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC.

Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. doi: 10.1586/14737140.8.7.1053. Review.

PMID:
18588451
[PubMed - indexed for MEDLINE]
4.

[Role of bortezomib in the treatment of multiple myeloma].

Gotoh A, Ohyashiki K.

Nihon Rinsho. 2007 Dec;65(12):2309-14. Review. Japanese.

PMID:
18069278
[PubMed - indexed for MEDLINE]
5.

A review of the proteasome inhibitor bortezomib in multiple myeloma.

Richardson PG.

Expert Opin Pharmacother. 2004 Jun;5(6):1321-31. Review.

PMID:
15163277
[PubMed - indexed for MEDLINE]
6.

Bortezomib in combination with other therapies for the treatment of multiple myeloma.

Orlowski RZ.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S16-20. Review.

PMID:
19791424
[PubMed - indexed for MEDLINE]
7.

Multiple myeloma.

Harousseau JL, Shaughnessy J Jr, Richardson P.

Hematology Am Soc Hematol Educ Program. 2004:237-56. Review.

PMID:
15561686
[PubMed - indexed for MEDLINE]
Free Article
8.

Proteasome inhibition in the treatment of cancer.

Richardson PG, Mitsiades C, Hideshima T, Anderson KC.

Cell Cycle. 2005 Feb;4(2):290-6. Epub 2005 Feb 3. Review.

PMID:
15655370
[PubMed - indexed for MEDLINE]
Free Article
9.

Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.

Cheriyath V, Jacobs BS, Hussein MA.

Drugs R D. 2007;8(1):1-12. Review.

PMID:
17249845
[PubMed - indexed for MEDLINE]
10.

Bortezomib combination therapy in multiple myeloma.

Kapoor P, Ramakrishnan V, Rajkumar SV.

Semin Hematol. 2012 Jul;49(3):228-42. doi: 10.1053/j.seminhematol.2012.04.010. Review.

PMID:
22726546
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Palumbo A, Attal M, Roussel M.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Review.

PMID:
21411441
[PubMed - indexed for MEDLINE]
Free Article
12.

Proteasome inhibition: novel therapy for multiple myeloma.

Kaufman JL, Lonial S.

Onkologie. 2006 Apr;29(4):162-8. Epub 2006 Mar 29. Review.

PMID:
16601373
[PubMed - indexed for MEDLINE]
13.

Discovery and development of second-generation proteasome inhibitors.

Kirk CJ.

Semin Hematol. 2012 Jul;49(3):207-14. doi: 10.1053/j.seminhematol.2012.04.007. Review.

PMID:
22726543
[PubMed - indexed for MEDLINE]
14.

Treatment of relapsed and refractory myeloma.

Kaufman J, Gleason C, Lonial S.

Curr Hematol Malig Rep. 2009 Apr;4(2):99-107. doi: 10.1007/s11899-009-0014-5. Review.

PMID:
20425421
[PubMed - indexed for MEDLINE]
15.

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.

Cancer. 2007 Sep 1;110(5):1042-9. Review.

PMID:
17654660
[PubMed - indexed for MEDLINE]
Free Article
16.

Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs.

Ocio EM, Mateos MV, San-Miguel JF.

Expert Opin Investig Drugs. 2012 Aug;21(8):1075-87. doi: 10.1517/13543784.2012.691164. Epub 2012 May 24. Review.

PMID:
22621161
[PubMed - indexed for MEDLINE]
17.

Myeloma: classification and risk assessment.

Fonseca R, Monge J.

Semin Oncol. 2013 Oct;40(5):554-66. doi: 10.1053/j.seminoncol.2013.07.002. Review.

PMID:
24135400
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk